NAFTIDROFURYL OXYLATE

Naftidrofuryl oxalate is a peripheral vasodilator that enhances tissue oxygenation by improving erythrocyte flexibility and inhibiting serotonin‑mediated vasoconstriction. It is used for peripheral arterial disease and intermittent claudication. Benefits include increased walking distance and reduced leg pain. Side effects include nausea, abdominal discomfort, diarrhea, dizziness, and, rarely, liver enzyme elevations or hypersensitivity reactions.

SKU: cd45bcc419c9 Category: Tag:

Product Description


Mechanism of Action

NAFTIDROFURYL OXYLATE (ID 26810) exhibits a multi‑vector biochemical action pattern, influencing enzymatic cascades, receptor‑mediated signalling, intracellular ion behaviour, mitochondrial oxidative dynamics and transcriptional regulatory networks. Its structural characteristics suggest interaction with catalytic residues, allosteric pockets and regulatory scaffolds, enabling modulation of phosphorylation circuits, second‑messenger systems (cAMP, Ca²⁺, IP₃), ROS generation, membrane polarization and metabolic‑flux channeling.

Depending on biological context, NAFTIDROFURYL OXYLATE may alter mitochondrial membrane potential, redox buffering capacity, calcium sequestration, cytoskeletal integrity, vesicle trafficking efficiency and transcription‑factor activation, resulting in broad mechanistic adaptability across experimental systems.

Benefits and Advantages

This compound is highly valued in advanced biochemical and pharmacological research frameworks, including:

  • High‑resolution receptor–ligand mapping and affinity prediction
  • Enzyme‑kinetic profiling and catalytic‑pathway deconstruction
  • Mitochondrial‑stress testing, ATP‑flux analysis and ROS‑equilibrium studies
  • Integrated multi‑omics research: transcriptomics, metabolomics, proteomics, phosphoproteomics
  • Cytoskeletal modelling involving actin/tubulin regulation
  • Apoptosis, autophagy, necroptosis and ferroptosis signalling investigations
  • Structure–activity relationship (SAR) exploration and molecular optimisation
  • Pharmacodynamic simulations for mechanistic threshold and dose‑response studies

Side Effects and Risks

Possible laboratory‑observed risks include:

  • Redox imbalance with elevated ROS levels
  • Mitochondrial overactivation or respiratory‑chain suppression
  • Ion‑channel dysregulation affecting Na⁺/K⁺/Ca²⁺ flow
  • Cross‑activation or inhibition of unintended receptor systems
  • Cytoskeletal destabilisation and impaired membrane integrity
  • Dose‑dependent cytotoxicity or induction of apoptotic/autophagic pathways
  • Transcriptional instability and activation of inflammatory cascades (NF‑κB, JNK, p38)

Strict biosafety handling, controlled dosing and regulated environmental conditions are required for all experimental use. Not intended for human or veterinary application.

Datasheet


Molecular Formula

C21H23NO5

Molecular Weight

353.41 g/mol

CAS Number

23256-30-6

Storage Condition

Store at 2-8°C

Solubility

Soluble in water

Purity

Purity information is available upon request (COA).

Synonym

N-(3-methyl-1,1-dioxo-1,4-thiazinan-4-yl)-1-(5-nitro-2-furanyl)methanimine; Prestwick0_001024; Prestwick1_001024; SCHEMBL60839; MLS002154109

IUPAC/Chemical Name

2-(diethylamino)ethyl 1-naphthoate oxalate

InChl Key

Unavailable

InChl Code

Unavailable

References

PubChem; ChemBL; FDA;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download